USFDA28 May 2025, 11:22 am
Zydus Lifesciences Receives USFDA 'Fast Track Designation' for Usnoflast to Treat Amyotrophic Lateral Sclerosis (ALS)
AI Summary
Zydus Lifesciences Ltd has received 'Fast Track Designation' from the USFDA for its novel oral NLRP3 inhibitor, Usnoflast, for the treatment of Amyotrophic Lateral Sclerosis (ALS). This comes after Usnoflast received 'Orphan Drug Designation (ODD)' from the USFDA. The 'Fast Track Designation' aims to expedite the development and review of new drugs to treat serious conditions or fill an unmet medical need. Usnoflast has shown potential in addressing the urgent need for ALS treatments, a fatal neurodegenerative disease affecting approximately 32,000 people in the U.S.A and 75,000 in India.
Key Highlights
- Zydus Lifesciences Ltd receives USFDA 'Fast Track Designation' for Usnoflast for the treatment of ALS.
- Usnoflast has previously received 'Orphan Drug Designation (ODD)' from the USFDA.
- Fast Track Designation aims to expedite development and review of new drugs for serious conditions.
- ALS is a fatal neurodegenerative disease affecting 32,000 people in the U.S.A and 75,000 in India.
- Usnoflast has shown potential in addressing the urgent need for ALS treatments.